Results 1 to 10 of about 212,526 (280)

Bruton’s Tyrosine Kinase: A Double-Edged Sword in Cancer and Aging [PDF]

Kinases and Phosphatases
Bruton’s tyrosine kinase (BTK) is a key signaling molecule involved in both hematological malignancies and solid tumors. In B-cell malignancies such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), BTK mediates B-cell receptor ...
Zahraa Qusairy, Miran Rada
doaj   +2 more sources

Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases [PDF]

Journal of Medicinal Chemistry, 2019
Bruton's tyrosine kinase (BTK) inhibitors such as ibrutinib hold a prominent role in the treatment of B cell malignancies. However, further refinement is needed to this class of agents, particularly in terms of adverse events (potentially driven by ...
Richard D. Caldwell, Hui Qiu, Ben Askew, Andrew T. Bender, Nadia Brügger, Montserrat Camps, Mohanraj Dhanabal, Vikram Dutt, Thomas Eichhorn, A.S. Gardberg, Andreas Goutopoulos, Roland Grenningloh, Jared Head, Brian Healey, Brian L. Hodous, Bayard R. Huck, Theresa Johnson, Christopher C. Jones, Reinaldo Jones, Igor Mochalkin, Federica Morandi, Thi Kim Ngan Nguyen, Michael Meyring, Justin R. Potnick, Dusica Santos, Ralf Schmidt, Brian Sherer, Adam Shutes, Klaus Urbahns, Ariele Viacava Follis, Ansgar Wegener, Simone C. Zimmerli, Lesley Liu‐Bujalski   +32 more
openalex   +2 more sources

Bruton's tyrosine kinase inhibition for the treatment of allergic disorders. [PDF]

Ann Allergy Asthma Immunol
IgE signaling through its high-affinity receptor FcεRI is central to the pathogenesis of numerous allergic disorders. Oral inhibitors of Bruton’s tyrosine kinase (BTKis), which are currently FDA-approved for the treatment of B cell malignancies, broadly ...
Lin EV, Suresh RV, Dispenza MC.
europepmc   +2 more sources

Spleen and Bruton's tyrosine kinase inhibitors for the management of adult immune thrombocytopenia: A systematic review and meta-analysis of randomized controlled trials. [PDF]

Clin Hematol Int
Vatvani AD, Hariyanto TI, Ramirez AC, Shabarek N.   +3 more
europepmc   +3 more sources

Patterns of Bruton's Tyrosine Kinase Inhibitor (BTKi) Usage in B-cell Lymphomas in India: A Questionnaire-Based Study. [PDF]

Cureus
Naseem A, Pednekar A, Patil S, Barkate H.   +3 more
europepmc   +3 more sources

Novel Bruton's tyrosine kinase inhibitor TAS5315 suppresses the progression of inflammation and joint destruction in rodent collagen-induced arthritis.

PLoS ONE, 2023
Rheumatoid arthritis is an inflammatory autoimmune disease, characterized by autoantibody production, synovial inflammation, and joint destruction. Its pathogenesis is due to environmental factors and genetic backgrounds.
Daichi Akasaka, Satoru Iguchi, Ryusuke Kaneko, Yohei Yoshiga, Daisuke Kajiwara, Yoshinori Nakachi, Naruto Noma, Kenji Tanaka, Atsushi Shimizu, Fumihito Hosoi   +9 more
doaj   +2 more sources

Economic Evaluation of Bruton's Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukaemia in South Africa. [PDF]

Appl Health Econ Health Policy
Woudberg R, Sinanovic E.
europepmc   +3 more sources

Bruton’s tyrosine kinase inhibition ameliorated neuroinflammation during chronic white matter ischemia [PDF]

Journal of Neuroinflammation
Chronic cerebral hypoperfusion (CCH), a disease afflicting numerous individuals worldwide, is a primary cause of cognitive deficits, the pathogenesis of which remains poorly understood. Bruton’s tyrosine kinase inhibition (BTKi) is considered a promising
Lu-Lu Xu, Sheng Yang, Luo-Qi Zhou, Yun-Hui Chu, Xiao-Wei Pang, Yun-Fan You, Hang Zhang, Lu-Yang Zhang, Li-Fang Zhu, Lian Chen, Ke Shang, Jun Xiao, Wei Wang, Dai-Shi Tian, Chuan Qin   +14 more
doaj   +2 more sources

PB1935: CARDIOTOXICITY AND SAFETY OF BRUTON’S TYROSINE KINASE INHIBITORS: A REVIEW OF REAL-WORLD OBSERVATIONAL EVIDENCE [PDF]

Hemasphere, 2023
Balijepalli C, Siliman G, Joshy J, Gullapalli L, Druyts E.   +4 more
europepmc   +2 more sources

ASK120067 potently suppresses B-cell or T-cell malignancies in vitro and in vivo by inhibiting BTK and ITK

Frontiers in Pharmacology, 2022
Hyperactivation of Bruton’s tyrosine kinase (BTK) or interleukin-2-inducible T cell kinase (ITK) has been attributed to the pathogenesis of B-cell lymphoma or T-cell leukemia, respectively, which suggests that Bruton’s tyrosine kinase and interleukin-2 ...
Peiran Song, Peiran Song, Gang Bai, Shingpan Chan, Tao Zhang, Linjiang Tong, Yi Su, Yanyan Shen, Yi Chen, Yingqiang Liu, Mengzhen Lai, Mengzhen Lai, Yi Ning, Haotian Tang, Yan Fang, Yi Chen, Ke Ding, Jian Ding, Jian Ding, Hua Xie, Hua Xie, Hua Xie   +21 more
doaj   +1 more source